Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prograf® (Tacrolimus) as Secondary Intervention vs. Continuation of Cyclosporine in Patients at Risk for Chronic Renal Allograft Failure

NCT00637143 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT00637143
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00637143 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prograf® (Tacrolimus) as Secondary Intervention vs. Continuation of Cyclosporine in Patients at Risk for Chronic Renal Allograft Failure
Lead sponsor
Astellas Pharma Inc
Phase
Phase 4
Overall status
Completed
Start date
April 30, 1999
Completion date
February 28, 2006
Enrollment
107 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

chronic renal allograft failure, renal transplantation